KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Net Margin (2018 - 2026)

Amneal Pharmaceuticals has reported Net Margin over the past 8 years, most recently at 6.09% for Q4 2025.

  • For Q4 2025, Net Margin rose 893.0% year-over-year to 6.09%; the TTM value through Dec 2025 reached 4.24%, up 688.0%, while the annual FY2025 figure was 4.24%, 842.0% up from the prior year.
  • Net Margin for Q4 2025 was 6.09% at Amneal Pharmaceuticals, up from 2.31% in the prior quarter.
  • Over five years, Net Margin peaked at 6.09% in Q4 2025 and troughed at 21.6% in Q2 2022.
  • A 5-year average of 1.46% and a median of 0.46% in 2021 define the central range for Net Margin.
  • Biggest five-year swings in Net Margin: tumbled -2431bps in 2022 and later surged 2359bps in 2023.
  • Year by year, Net Margin stood at 1.19% in 2021, then soared by 40bps to 0.71% in 2022, then plummeted by -2150bps to 15.99% in 2023, then skyrocketed by 82bps to 2.84% in 2024, then soared by 314bps to 6.09% in 2025.
  • Business Quant data shows Net Margin for AMRX at 6.09% in Q4 2025, 2.31% in Q3 2025, and 4.92% in Q2 2025.